Abstract
In medically complex patients with multiple comorbid illnesses who require concomitant medications, selecting the optimal antidepressant (ie, low risk of adverse effects and/or pharmacokinetic interactions) for an individual patient is critical for positive long-term patient outcomes. The serotonin-norepinephrine reuptake inhibitors (SNRls) are increasingly being used as first-line treatment for major depressive disorder (MDD) and may prove beneficial for treatment of medically complex patients.Thus, it is key for clinicians to evaluate the differences in the pharmacokinetic and tolerability profiles of the SNRI class of antidepressants, evaluating differences both within the class and compared with other antidepressants used to treat MDD.
Original language | English (US) |
---|---|
Pages (from-to) | 20-27 |
Number of pages | 8 |
Journal | CNS spectrums |
Volume | 14 |
Issue number | 12 Suppl 12 |
State | Published - Dec 2009 |
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health